Dr. Steven Nissen is preparing for a mixed response at the American Heart Association’s annual conference on Saturday as he prepares to present the results of a significant study concerning the experimental drug pelacarsen, designed to reduce the risk of heart attacks and strokes. Many in the audience are already aware that the trial did not achieve its primary goal of decreasing the incidence of major cardiovascular events linked to elevated lipoprotein (a), or Lp(a), a type of fat in the blood, reports BritPanorama.
Nissen, a preventive cardiologist at the Cleveland Clinic, anticipates that the crowd will respond with disappointment as he informs them that pelacarsen failed to show the expected efficacy. “I’m going to have to weather the gasp in the audience,” he remarked.
Despite initial hopes for pelacarsen, the drug ultimately did not fulfill its promise. While it succeeded in lowering Lp(a) levels by an average of approximately 77% in those receiving it, there was no discernible reduction in cardiovascular events compared to the placebo group. “It wasn’t a near miss. It just didn’t have an effect on outcomes, and I don’t think virtually anybody’s prepared to hear that,” Nissen explained. This outcome has led to the decision by Novartis, the drug’s manufacturer, to discontinue its development.
No breakthrough for patients yet
In the realm of scientific research, the implications of failed trials can be as profound as those of successful ones. The findings surrounding pelacarsen challenge existing notions regarding the role of Lp(a) in heart disease, prompting a reevaluation among cardiologists.
Over a span of seven years, Nissen and his team conducted extensive research on pelacarsen, which was designed to inhibit the production of Lp(a). Elevated levels of Lp(a) are correlated with increased clotting and inflammation in the arteries, heightening the risk for heart attacks. The study involved 8,350 participants who had previously experienced cardiovascular events, dividing them into two groups: one receiving pelacarsen and the other a placebo, with roughly equal follow-ups.
At the study’s conclusion, the anticipated outcomes measured by major adverse cardiovascular events (MACE) revealed no difference between the groups, with approximately 12% of patients in both cohorts experiencing serious cardiovascular incidents.
These results were published in the New England Journal of Medicine. Nissen expressed concern over the perception that pelacarsen was a failure when describing the study as the first of its kind targeting a disorder prevalent among over a billion individuals globally. He stated that the expectation for positive results was high, thus the outcome has left many in the medical community surprised.
What now?
The recent guidelines from the American Heart Association and the American College of Cardiology now recommend that all adults undergo testing for Lp(a) at least once during their lifetime. While some experts argue for the necessity of such screening, others express caution, as there currently exist no therapies directly addressing the high levels of Lp(a).
Dr. Karol Watson of UCLA suggested that it may be premature to endorse universal screening without concrete treatment options, emphasizing the need for more definitive interventions for identified risks. Meanwhile, advocates for testing insist that knowing a patient’s Lp(a) level provides significant insight into their heart disease risk.
Recent clinical trials have suggested alternative Lp(a)-lowering medications are in development, with some experts believing these may prove beneficial if administered early in the disease process. “What we’ve done now is set up a whole bunch of people who are really anxious about this now, and we still tell them we have nothing to offer them,” Watson commented.
Lessons from a failed trial
While the trial led by Nissen is categorized as a failed trial, experts, including Dr. Fatima Rodriguez from Stanford, contend that such negative results can yield essential insights. Clear outcomes from well-conducted trials can prove invaluable, urging researchers to reconsider existing theories about heart disease mechanisms.
Nissen postulates that the age and health condition of trial participants may have influenced the results, indicating that patients in older demographics might obtain limited benefits from lowering Lp(a) if their other risk factors are not adequately managed. He has proposed that ideally, treatment should lower Lp(a) levels to around 90% or 95% to potentially exhibit a tangible decrease in heart disease risk.
Nissen remains committed, indicating plans to continue current trials on new Lp(a)-lowering medications, recognizing the continuing struggles against cardiovascular disease.
The journey towards medical advancements continues to be fraught with challenges, reflecting the ongoing quest for effective treatments and conduct in heart health research.
